Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)

Abstract

Background: Bevacizumab-awwb (MVASI®) was the first U.S. Food and Drug Administration-approved biosimilar to Avastin® (reference product [RP]) for the treatment of several different types of cancers, including metastatic colorectal cancer (mCRC), an indication approved based on extrapolation. Objectives: Evaluate treatment outcomes in mCRC patients who received first-line (1L) bevacizumab-awwb at treatment initiation or as continuing bevacizumab therapy (switched from RP). Design: A retrospective chart review study. Methods: Adult patients who had a confirmed diagnosis of mCRC (initial presentation of CRC on or after 01 January 2018) and initiated 1L bevacizumab-awwb between 19 July 2019 and 30 April 2020 were identified from the ConcertAI Oncology Dataset. A chart review was conducted to evaluate patient baseline clinical characteristics and effectiveness and tolerability outcomes during the follow-up. Study measures were reported stratified by prior use of RP: (1) naïve patients and (2) switchers (patients who switched to bevacizumab-awwb from RP without advancing the line of therapy). Results: At the end of study period, naïve patients ( n = 129) had a median 1L progression-free survival (PFS) of 8.6 months [95% confidence interval (CI), 7.6–9.9] and a 12-month overall survival (OS) probability of 71.4% (95% CI, 61.0–79.5%). Switchers ( n = 105) had a median 1L PFS of 14.1 months (95% CI, 12.1–15.8) and a 12-month OS probability of 87.6% (95% CI, 79.1–92.8%). During treatment with bevacizumab-awwb, 20 events of interest (EOIs) were reported in 18 naïve patients (14.0%) and 4 EOIs reported in 4 switchers (3.8%), of which the most commonly reported events were thromboembolic and hemorrhagic events. Most EOIs resulted in emergency department visit and/or treatment hold/discontinuation/switch. None of the EOIs resulted in death. Conclusion: In this real-world cohort of mCRC patients who were treated 1L with a bevacizumab biosimilar (bevacizumab-awwb), the clinical effectiveness and tolerability data were as expected and consistent with previously published findings from real-world studies of bevacizumab RP in mCRC patients.

Evaluation of bevacizumab biosimilar on wound healing complications in patients with colorectal cancer undergoing endoscopic mucosal resection: A systematic review and meta‐analysis in anorectal medicine

“…In the 2023 study conducted by Jin et al 17 the experimental group had an average success rate of 87.6% compared with the control group's 71.4%. This represented the notable difference of 16.2%, indicating that the intervention had significant effect.…”

“…In addition to efficacy and safety, duration of therapeutic effectiveness was of interest. In a number of studies, including those by Jin et al 17 and Saab et al 18 the experimental groups exhibited longer durations of efficacy. However, caution is required when interpreting these results.…”

“…The comprehensive summary of studies that investigated treatments for mCRC, with an emphasis on bevacizumab and its biosimilars revealed that Jin et al 17 assessed the efficacy of bevacizumab‐awwb treatment in adult patients with mCRC. Their primary outcomes were thromboembolic and hemorrhagic events, but none of these resulted in fatalities.…”

“…Consistent with the current literature on biosimilars, our analysis demonstrated that the reference product, Bevacizumab, and its biosimilars have comparable efficacy and safety. Several studies, including Jin et al 17 and Saab et al 18 found that experimental groups treated with biosimilars exhibited greater efficacy than control groups. Although not all studies exhibited the same degree of disparity, there was a discernible pattern of the experimental group outperforming the control.…”